This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Douglas E. Jorenby, PhD; Stevens S. Smith, PhD; Michael C. Fiore, MD, MPH; Timothy B. Baker, PhD
University of Wisconsin Medical School Madison

Richard D. Hurt, MD; Kenneth P. Offord, MS
Mayo Clinic Rochester, Minn

JAMA. 1996;275(24):1882-1883.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Drs Westman and Rose raise important concerns aimed at the therapeutic usefulness of the 44-mg nicotine patch dose compared with the 22-mg dose. We confess to being surprised ourselves, as intuitively we expected a larger dose might be more effective, just as we expected more intensive behavioral intervention would be more effective; neither produced a long-term efficacious advantage. The 44-mg dose showed higher efficacy in the minimum intervention group at 4 weeks (which was the duration of the 44-mg dose), but did not produce sustained benefit relative to the 22-mg dose.

Westman and Rose cite research on 2- and 4-mg nicotine gum as a reason for expecting a doubling of the patch dose to be effective. The many differences between nicotine patches and gum (eg, route of administration, lower amount of nicotine per dose, self-dosing, and pharmacokinetics) make it difficult to compare the 2 products.

While it may . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?